Lung barrier disruption and Sp dissemination also depended on 12-LOX activity because CDC treatment of Sp-infected mice resulted in lower FITC-dextran leakage (P < 0.01; Fig. 1c) and bacteremia at 18 h.p.i. (P < 0.01; Fig. 1d). This evidence concerns the gene TFF2 and bacterial infectious disease with sepsis.